EMSY抗体;EMSY Antibody—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human colorectal cancer tissue using P13316(EMSY Antibody) at dilution 1/20. (Original magnification: ×200)    

  
  

The EMSY antibody is a research tool targeting the EMSY protein, encoded by the *EMSY* gene located on chromosome 11q13. First identified in 2003. EMSY gained attention due to its interaction with BRCA2. a tumor suppressor critical in DNA repair. EMSY binds to the transactivation domain of BRCA2. potentially inhibiting its function in homologous recombination repair (HRR), a pathway vital for maintaining genomic stability. Overexpression or amplification of *EMSY* has been linked to sporadic breast and ovarian cancers, mirroring phenotypes seen in BRCA2-deficient tumors, earning it the nickname "BRCA2-associated factor."

EMSY antibodies are primarily used to study protein expression, localization, and interaction networks in cancer models. They aid in identifying EMSY's role in transcriptional regulation, chromatin remodeling, and DNA damage response. Clinically, EMSY _expression (detected via IHC or Western blot using specific antibodies) has been explored as a prognostic biomarker, particularly in triple-negative breast cancer and high-grade serous ovarian carcinoma. However, findings remain controversial, partly due to variability in antibody specificity and assay conditions. Recent studies also investigate EMSY's interplay with other oncogenic pathways, such as PI3K/AKT, highlighting its potential as a therapeutic target. Validated EMSY antibodies are crucial for clarifying its dual roles in tumor suppression and oncogenesis, depending on cellular context.